Adipex-P is a prescription weight-management medication containing phentermine hydrochloride. It belongs to a group of medicines known as sympathomimetic amines and works primarily by reducing appetite through effects on the central nervous system.
Adipex-P is intended to be used as one part of a broader weight-reduction program that includes appropriate calorie restriction, physical activity, and behavioral changes. The FDA labeling describes it as a short-term adjunct for certain adults with obesity or overweight accompanied by weight-related risk factors.
Phentermine is not simply a medication designed to produce rapid weight loss without lifestyle changes. Its approved role is to support a structured weight-management plan by helping reduce appetite, which may make it easier for some patients to follow a calorie-controlled eating plan.
Because phentermine stimulates the central nervous system and has sympathomimetic effects, it requires careful consideration of cardiovascular health, blood pressure, psychiatric history, other medications, and potential for misuse or dependence.
This guide explains what Adipex is, how phentermine works, who may be prescribed it, dosing principles, side effects, contraindications, interactions, dependence concerns, special-population considerations, and important safety information.
Adipex-P is a brand formulation of phentermine hydrochloride.
Phentermine is classified as a sympathomimetic amine anorectic, meaning that it is an appetite-suppressing medication with stimulant-like effects on the nervous system.
In the United States, phentermine is a Schedule IV controlled substance. This classification reflects its potential for misuse and dependence and means that it is subject to prescription and controlled-substance regulations.
Adipex-P has been available for many years and was originally approved in the United States in 1959. The FDA labeling describes it as a short-term treatment used together with exercise, behavioral modification, and caloric restriction.
The active ingredient in Adipex-P is:
Phentermine hydrochloride
The commonly marketed Adipex-P tablet and capsule contain 37.5 mg of phentermine hydrochloride, equivalent to 30 mg of phentermine base.
The strength printed on a prescription should always be checked carefully because different phentermine products can have different formulations and strengths.
Adipex-P is indicated as a short-term adjunct to weight reduction in certain patients with obesity.
The FDA labeling describes use in adults with an initial:
BMI of 30 kg/m² or greater, or
BMI of at least 27 kg/m² when additional risk factors are present
Examples of weight-related risk factors identified in the labeling include controlled hypertension, diabetes, and hyperlipidemia.
The medication is intended to be used as part of a comprehensive weight-reduction program.
That program can involve:
Calorie reduction
Dietary modification
Physical activity
Behavioral changes
Regular medical follow-up
Weight loss generally requires an energy deficit over time. However, maintaining a reduced-calorie diet can be difficult when hunger is persistent.
An appetite-suppressing medication may help some patients experience less hunger or reduced food intake, making a structured dietary plan easier to follow.
The medication does not replace healthy eating or physical activity. Instead, its purpose is to support the broader weight-management plan.
Phentermine has sympathomimetic effects.
It stimulates certain pathways involving naturally occurring neurotransmitters, particularly norepinephrine. The resulting activity can reduce appetite and increase central nervous system stimulation.
In practical terms, patients may experience:
Reduced hunger
Increased sense of fullness
Greater ability to follow a calorie-controlled diet
Increased alertness or stimulation in some individuals
The same pharmacologic activity responsible for appetite suppression can also contribute to unwanted effects such as:
Increased heart rate
Elevated blood pressure
Nervousness
Restlessness
Tremor
Difficulty sleeping
This explains why cardiovascular and psychiatric history are important when determining whether phentermine is appropriate.
It is important to distinguish appetite suppression from permanent weight management.
Adipex can reduce appetite while it is being used, but long-term weight maintenance depends on broader factors, including:
Dietary patterns
Physical activity
Sleep
Metabolic health
Medical conditions
Behavioral habits
Access to appropriate healthcare
Individual response to treatment
The FDA labeling also notes that the natural history of obesity occurs over years, while the clinical studies supporting these older short-term anorectic agents were conducted over much shorter periods.
Therefore, treatment should be periodically reassessed rather than assuming that continued medication automatically produces continued benefit.
The appropriate dose should be individualized by a healthcare professional, with the goal of obtaining an adequate response using the lowest effective dose.
The historical FDA labeling for Adipex-P describes a usual adult dose of 37.5 mg once daily, with some patients potentially requiring a lower dose depending on clinical circumstances.
Because phentermine products can differ in strength and formulation, the instructions on the actual prescription should take precedence over general dosing information.
Adipex-P is generally taken in the morning.
Late-evening administration should be avoided because the stimulant-like effects can cause or worsen insomnia.
Taking the medicine later in the day does not necessarily improve weight-management results and may instead interfere with nighttime sleep.
The FDA labeling indicates that Adipex-P may be taken with or without food.
Patients should follow the directions supplied with their specific prescription.
Phentermine affects the central nervous system and cardiovascular system. More medication does not necessarily mean better weight-management results.
Higher-than-prescribed exposure may increase the risk of:
Rapid heartbeat
Elevated blood pressure
Anxiety
Restlessness
Tremor
Insomnia
Agitation
Other stimulant-related effects
Using more than prescribed also increases the potential for misuse and dependence.
Patients should never increase their dose because they believe the medication is no longer working as strongly.
Instead, reduced effectiveness should be discussed with the prescribing clinician.
Important principles include:
Take the medication exactly as prescribed.
Follow the prescribed strength.
Take it at the recommended time.
Avoid taking it late in the evening.
Do not take additional doses to compensate for a missed dose.
Do not combine it with another weight-loss medicine unless specifically directed.
Tell your healthcare professional about all prescription and nonprescription medicines.
Report significant cardiovascular symptoms.
Report severe mood or behavioral changes.
Keep the medication securely stored.
Because Adipex is a controlled prescription medication, it should never be shared with another person.
Phentermine can cause stimulant-like adverse effects.
Possible side effects include:
Dry mouth
Insomnia
Nervousness
Restlessness
Increased heart rate
Increased blood pressure
Tremor
Headache
Dizziness
Gastrointestinal discomfort
Constipation
Unpleasant taste
The intensity of side effects can vary considerably between individuals.
For some people, stimulant effects may be mild. For others, they may be significant enough to interfere with sleep, daily activities, or quality of life.
Insomnia is an especially important consideration with phentermine.
Because the medication stimulates the nervous system, taking it later in the day may make it more difficult to fall asleep.
Poor sleep can also complicate weight-management efforts because inadequate sleep may affect:
Hunger
Appetite regulation
Energy
Mood
Exercise tolerance
Food choices
For this reason, the FDA labeling specifically advises avoiding late-evening administration.
Phentermine can affect the cardiovascular system.
Potential concerns include:
Increased heart rate
Increased blood pressure
Palpitations
Chest discomfort
Other cardiovascular symptoms
Patients with certain cardiovascular conditions should not use Adipex-P.
The FDA labeling lists a history of cardiovascular disease—including coronary artery disease, stroke, arrhythmias, congestive heart failure, and uncontrolled hypertension—as a contraindication.
Anyone taking phentermine who develops concerning chest pain, fainting, severe shortness of breath, or a markedly abnormal heartbeat should seek urgent medical evaluation.
Rare but serious pulmonary complications have been associated with appetite-suppressant medications.
Patients should be aware of symptoms such as:
Unexplained shortness of breath
Chest discomfort
Reduced exercise tolerance
Fainting
Swelling associated with cardiovascular problems
These symptoms require medical evaluation rather than being assumed to be an ordinary medication side effect.
Historical concerns surrounding anorectic medications include pulmonary hypertension and cardiac valvular disease.
The FDA labeling discusses these rare but potentially serious conditions and emphasizes that the risks of treatment should be considered in relation to the limited usefulness of short-term appetite-suppressant therapy.
Patients should report unexplained breathing difficulties, chest symptoms, or reduced exercise tolerance.
Because phentermine stimulates the nervous system, some patients may experience psychological or behavioral changes.
Possible effects include:
Anxiety
Irritability
Restlessness
Agitation
Nervousness
Difficulty concentrating
Mood changes
Patients with a history of significant psychiatric symptoms should discuss that history with the prescribing clinician before treatment.
The FDA labeling specifically lists agitated states as a contraindication.
Phentermine is a controlled substance because it has the potential for abuse and dependence.
Dependence means the body can adapt to repeated exposure to the medication.
Misuse can involve taking the medication in a way that differs from the prescription, such as taking more than prescribed or using someone else's medication.
The risk of problematic use is particularly important in patients with a personal history of substance misuse.
The FDA labeling lists a history of drug abuse as a contraindication for Adipex-P.
Tolerance refers to reduced response to a medication after repeated exposure.
With phentermine, patients should not respond to perceived tolerance by independently increasing the dose.
If appetite suppression appears to decrease, a clinician may need to reassess:
The overall weight-management plan
Dietary habits
Activity level
Other medications
Medical conditions
Whether continued phentermine treatment is appropriate
Self-directed dose escalation can increase adverse effects and controlled-substance risks.
Phentermine should not be treated as a medication that can simply be taken indefinitely without review.
The appropriate approach to discontinuation depends on the duration of use, dose, individual response, and clinical circumstances.
Patients should speak with their healthcare professional before making significant changes to regular treatment.
A sudden change in medication may also affect appetite, energy, mood, or sleep.
The FDA labeling for Adipex-P states that it is intended as short-term monotherapy and that the safety and effectiveness of combining it with other weight-loss drugs have not been established.
This is important because modern weight management may involve many different medication classes.
Examples include:
GLP-1 receptor agonists
Other appetite-suppressing medicines
Combination weight-management products
Over-the-counter weight-loss products
Herbal supplements
Patients should not combine these products on their own.
A medication or supplement marketed as “natural” is not necessarily free from cardiovascular or stimulant effects.
The FDA labeling states that safety and effectiveness have not been established for combining Adipex-P with certain serotonergic agents, including SSRIs.
This does not mean that every patient taking an antidepressant will necessarily experience a serious interaction, but it does mean the combination should be evaluated by the prescribing clinician.
Patients should provide a complete medication list, including:
Antidepressants
Migraine medicines
Stimulants
ADHD medicines
Decongestants
Herbal supplements
Weight-loss products
Adipex-P is contraindicated during treatment with monoamine oxidase inhibitors (MAOIs) and for 14 days following MAOI treatment.
This is an important interaction because MAOIs can significantly affect neurotransmitter pathways involved in cardiovascular and nervous-system regulation.
Anyone taking or recently taking an MAOI should tell their healthcare professional before receiving phentermine.
High blood pressure requires careful evaluation before phentermine treatment.
The FDA labeling specifically lists uncontrolled hypertension as a cardiovascular contraindication.
Patients with controlled hypertension may be considered differently depending on their individual clinical circumstances, but blood pressure should be monitored appropriately.
Patients should report symptoms such as:
Severe headache
Chest pain
Significant palpitations
Shortness of breath
Fainting
Hyperthyroidism is listed as a contraindication to Adipex-P.
An overactive thyroid can already produce symptoms such as:
Rapid heartbeat
Tremor
Anxiety
Heat intolerance
Weight loss
Adding a sympathomimetic medication can potentially worsen these effects.
Patients with thyroid disease should disclose their diagnosis and current treatment.
Glaucoma is also listed among the contraindications in the FDA labeling.
Patients with glaucoma or elevated eye pressure should therefore discuss their eye history before treatment.
New visual symptoms, severe eye pain, or sudden changes in vision require prompt medical evaluation.
Adipex-P should not be used during pregnancy.
Weight loss provides no benefit during pregnancy for the treatment of obesity and may potentially harm fetal development.
The FDA labeling specifically lists pregnancy as a contraindication.
Anyone who becomes pregnant while taking phentermine should contact the prescribing healthcare professional promptly to discuss the medication.
The FDA labeling also lists nursing as a contraindication for Adipex-P.
Patients who are breastfeeding should not assume that phentermine is appropriate simply because the dose is relatively small.
Anyone who is pregnant, planning pregnancy, or breastfeeding should discuss weight-management treatment with a qualified healthcare professional.
Older adults may be more vulnerable to medication-related adverse effects.
Important considerations include:
Cardiovascular health
Blood pressure
Heart rhythm
Kidney function
Other prescription medications
Sensitivity to stimulant effects
Risk of insomnia
Risk of dizziness or falls
The FDA labeling recommends careful dose selection in older patients, particularly because renal function may decline with age and phentermine is substantially excreted by the kidneys.
Kidney function can affect the body's handling of phentermine.
Patients with impaired renal function should tell their healthcare professional before treatment.
This is particularly important in older adults or people with known kidney disease.
The prescriber may consider kidney function when determining whether the medicine is appropriate and which dose is suitable.
Phentermine is not primarily dependent on the liver in the same way as many other medications, but patients with significant liver disease should still disclose their medical history.
Treatment decisions should consider the patient's complete medical condition and all medications being used.
Phentermine may affect alertness, concentration, or judgment in some people.
Patients should determine how the medication affects them before driving or performing hazardous activities.
Particular caution is appropriate when treatment is first started or when the dose changes.
If a dose is missed, patients should follow the instructions provided by their healthcare professional.
Do not take extra phentermine to compensate for a missed dose.
Because late-day administration can contribute to insomnia, taking a missed dose late in the day may be inappropriate.
When uncertain, a pharmacist or prescribing clinician can provide formulation-specific instructions.
An overdose of phentermine can cause excessive stimulant effects.
Potential symptoms may include:
Restlessness
Tremor
Agitation
Confusion
Rapid heartbeat
Increased blood pressure
Abnormal heart rhythm
Severe anxiety
Gastrointestinal symptoms
Seizures
Loss of consciousness in severe cases
A suspected overdose requires urgent medical evaluation.
Do not attempt to manage a suspected significant overdose at home.
Weight should not be the only factor monitored during treatment.
Healthcare professionals may also evaluate:
Blood pressure
Heart rate
Appetite response
Weight trajectory
Sleep quality
Anxiety or agitation
Medication adherence
Potential misuse
Other medications
Overall cardiovascular health
If expected benefits are not occurring, continuing the medication without reassessment may not be appropriate.
Medication works best when incorporated into a broader approach.
A sustainable dietary plan should provide adequate nutrition while supporting an appropriate calorie deficit.
Activity can support cardiovascular health, muscle preservation, metabolic health, and long-term weight maintenance.
Long-term success may depend on recognizing triggers for overeating, managing routines, improving sleep, and developing sustainable habits.
Underlying conditions such as thyroid disease, diabetes, sleep disorders, medication-related weight gain, and hormonal problems may affect weight management.
Adipex should therefore be considered a component of treatment rather than the entire treatment strategy.
The FDA labeling for Adipex-P describes it as a short-term adjunct, meaning use over a period of a few weeks.
Patients should not assume that because phentermine has been prescribed once, it should automatically be continued indefinitely.
The duration of therapy should be determined by the prescribing clinician based on:
Response
Safety
Medical history
Weight-management goals
Adverse effects
Risk factors
Overall benefit versus risk
Longer treatment decisions should be individualized and medically supervised.
Weight regulation involves multiple biological and behavioral mechanisms.
When a person loses weight, appetite and energy expenditure can change. Returning to previous eating patterns can also result in weight regain.
This means that stopping an appetite suppressant does not automatically preserve the weight loss achieved during treatment.
Long-term weight maintenance may require continued attention to:
Food intake
Physical activity
Sleep
Stress
Behavioral habits
Medical conditions
This is one reason healthcare professionals often focus on sustainable habits rather than medication alone.
Storage and Safe Handling
Adipex-P should be stored according to the product's labeling.
General principles include:
Keep it in its original container.
Keep it at the recommended room temperature.
Keep the container tightly closed.
Protect it from inappropriate heat or moisture.
Keep it away from children and pets.
Do not share the medication.
The FDA labeling describes storage at 20°C to 25°C (68°F to 77°F) and recommends keeping the medicine out of reach of children.
Because phentermine is a controlled substance, secure storage is especially important.
Safe Disposal
Unused phentermine should not be given to another person.
Patients should use an appropriate medication take-back program or follow local pharmacy and disposal guidance.
If the prescription container includes specific disposal instructions, those instructions should be followed.
Adipex-P is a brand-name product containing phentermine hydrochloride. Phentermine is the active ingredient.
Phentermine has sympathomimetic stimulant-like effects on the central nervous system and can cause increased alertness, nervousness, insomnia, increased heart rate, and other stimulant effects.
Adipex-P is indicated as a short-term adjunct to exercise, behavioral modification, and caloric restriction for certain patients with obesity or overweight accompanied by specified risk factors.
No. It is a prescription medication with specific indications and contraindications. A healthcare professional must determine whether it is appropriate.
The FDA labeling advises avoiding late-evening administration because it can cause insomnia.
Do not combine weight-loss medications on your own. The FDA labeling states that the safety and effectiveness of combination therapy with Adipex-P and other weight-loss products have not been established.
Yes. Phentermine can produce cardiovascular effects, including increased blood pressure and heart rate.
It depends on the individual's condition. Uncontrolled hypertension is listed as a contraindication. Patients with controlled hypertension require individualized medical evaluation.
Yes. Insomnia is a recognized concern, which is why late-evening administration should be avoided.
Phentermine is a controlled substance and has abuse and dependence potential. It should be taken only according to the prescription.
No. Pregnancy is listed as a contraindication for Adipex-P.
The FDA labeling lists nursing as a contraindication for Adipex-P.
Do not increase the dose yourself. Reduced effectiveness should be discussed with the prescribing clinician.
No medication guarantees permanent weight reduction. Long-term weight management generally requires sustainable changes in diet, activity, behavior, and medical care.
If you have been taking it regularly, discuss discontinuation with your healthcare professional rather than changing treatment independently.
Adipex-P contains phentermine, a prescription sympathomimetic appetite suppressant used as a short-term adjunct to a structured weight-reduction program.
The most important safety points are:
Use only under appropriate medical supervision.
Follow the prescribed dose.
Do not take extra doses when appetite suppression seems weaker.
Avoid late-evening administration because of insomnia risk.
Tell your healthcare professional about heart disease and high blood pressure.
Do not use Adipex-P during pregnancy or nursing.
Do not use it with an MAOI or within 14 days after an MAOI.
Do not combine it with other weight-loss medicines unless specifically directed.
Tell your healthcare professional about antidepressants, stimulants, decongestants, and supplements.
Be alert for cardiovascular symptoms.
Be alert for significant anxiety, agitation, or other behavioral changes.
Keep the medication secured because phentermine is a controlled substance.
Do not share the prescription.
Seek urgent medical attention for severe chest pain, fainting, severe shortness of breath, severe cardiovascular symptoms, or suspected overdose.
The FDA labeling emphasizes that Adipex-P is intended for short-term use as part of a comprehensive weight-reduction program and that its potential risks must be weighed against its expected benefit.
This chapter is provided for general educational and informational purposes. It does not replace an individualized medical evaluation, diagnosis, or treatment plan from a qualified healthcare professional.
Medication decisions should take into account a person's medical history, current medications, cardiovascular health, blood pressure, kidney function, pregnancy or breastfeeding status, and other relevant clinical factors.
Do not start, stop, increase, decrease, or combine prescription medicines based solely on information in this chapter.
For questions about Adipex-P or phentermine, patients should consult a physician, pharmacist, or other appropriately qualified healthcare professional.
Pillspanacea provides general medication and health information for educational purposes and should not be considered a substitute for professional medical care.